- Home
- OTLK vs BRLT Comparison
OTLK vs BRLT Comparison
Compare OTLK & BRLT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- OTLK
- BRLT
- Stock Information
- Founded
- OTLK 2010
- BRLT 2005
- Country
- OTLK United States
- BRLT United States
- Employees
- OTLK N/A
- BRLT N/A
- Industry
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- BRLT Consumer Specialties
- Sector
- OTLK Health Care
- BRLT Consumer Discretionary
- Exchange
- OTLK Nasdaq
- BRLT Nasdaq
- Market Cap
- OTLK 42.8M
- BRLT 36.6M
- IPO Year
- OTLK 2016
- BRLT 2021
- Fundamental
- Price
- OTLK $1.15
- BRLT $2.19
- Analyst Decision
- OTLK Buy
- BRLT Hold
- Analyst Count
- OTLK 5
- BRLT 2
- Target Price
- OTLK $5.25
- BRLT $1.80
- AVG Volume (30 Days)
- OTLK 2.7M
- BRLT 117.2K
- Earning Date
- OTLK 08-14-2025
- BRLT 11-06-2025
- Dividend Yield
- OTLK N/A
- BRLT N/A
- EPS Growth
- OTLK N/A
- BRLT N/A
- EPS
- OTLK N/A
- BRLT N/A
- Revenue
- OTLK $1,505,322.00
- BRLT $422,218,000.00
- Revenue This Year
- OTLK N/A
- BRLT $5.55
- Revenue Next Year
- OTLK $343.94
- BRLT $3.88
- P/E Ratio
- OTLK N/A
- BRLT N/A
- Revenue Growth
- OTLK N/A
- BRLT N/A
- 52 Week Low
- OTLK $0.79
- BRLT $1.25
- 52 Week High
- OTLK $6.98
- BRLT $3.10
- Technical
- Relative Strength Index (RSI)
- OTLK 46.22
- BRLT 47.60
- Support Level
- OTLK $1.04
- BRLT $1.98
- Resistance Level
- OTLK $1.13
- BRLT $2.10
- Average True Range (ATR)
- OTLK 0.07
- BRLT 0.16
- MACD
- OTLK 0.05
- BRLT -0.04
- Stochastic Oscillator
- OTLK 84.91
- BRLT 25.97
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.
About BRLT Brilliant Earth Group Inc.
Brilliant Earth Group Inc is a digitally native omnichannel jewelry company. The company designs, procures and sells ethically-sourced diamonds, gemstones and jewelry online and through showrooms. The sales of the company consist of revenue from diamond, gemstone, and jewelry retail sales. The company sells its products in the U.S. and other international countries, of which a majority of revenue is derived from the U.S.